CN100381125C - 一种治疗心脑血管病的药物组合物 - Google Patents
一种治疗心脑血管病的药物组合物 Download PDFInfo
- Publication number
- CN100381125C CN100381125C CNB2003101110640A CN200310111064A CN100381125C CN 100381125 C CN100381125 C CN 100381125C CN B2003101110640 A CNB2003101110640 A CN B2003101110640A CN 200310111064 A CN200310111064 A CN 200310111064A CN 100381125 C CN100381125 C CN 100381125C
- Authority
- CN
- China
- Prior art keywords
- stem
- leaf
- radix ginseng
- breviscapine
- ginseng saponin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title abstract description 8
- 230000000747 cardiac effect Effects 0.000 title 1
- 230000002490 cerebral effect Effects 0.000 title 1
- 208000019553 vascular disease Diseases 0.000 title 1
- 241000208340 Araliaceae Species 0.000 claims abstract description 99
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 99
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 99
- 235000008434 ginseng Nutrition 0.000 claims abstract description 99
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract description 77
- 229930182490 saponin Natural products 0.000 claims abstract description 77
- 150000007949 saponins Chemical class 0.000 claims abstract description 77
- DJSISFGPUUYILV-UHFFFAOYSA-N UNPD161792 Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-UHFFFAOYSA-N 0.000 claims abstract description 65
- DJSISFGPUUYILV-ZFORQUDYSA-N scutellarin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-ZFORQUDYSA-N 0.000 claims abstract description 65
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 19
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 13
- 230000002526 effect on cardiovascular system Effects 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 238000002347 injection Methods 0.000 claims description 15
- 239000007924 injection Substances 0.000 claims description 15
- 239000000284 extract Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 3
- -1 transfusion Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 29
- 230000000694 effects Effects 0.000 abstract description 28
- 210000004369 blood Anatomy 0.000 abstract description 22
- 239000008280 blood Substances 0.000 abstract description 22
- 230000017531 blood circulation Effects 0.000 abstract description 14
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 230000001976 improved effect Effects 0.000 abstract description 2
- NPLTVGMLNDMOQE-UHFFFAOYSA-N carthamidin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=C(O)C(O)=C2C(=O)C1 NPLTVGMLNDMOQE-UHFFFAOYSA-N 0.000 abstract 2
- 229930190376 scutellarin Natural products 0.000 abstract 2
- 230000004087 circulation Effects 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 208000007536 Thrombosis Diseases 0.000 description 15
- 210000003743 erythrocyte Anatomy 0.000 description 14
- 238000012360 testing method Methods 0.000 description 12
- 229940079593 drug Drugs 0.000 description 10
- 206010008118 cerebral infarction Diseases 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 210000001715 carotid artery Anatomy 0.000 description 6
- 210000001168 carotid artery common Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000012891 Ringer solution Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 239000009636 Huang Qi Substances 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 229920001503 Glucan Polymers 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000000269 carotid artery external Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 3
- 238000003305 oral gavage Methods 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229960002275 pentobarbital sodium Drugs 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229920002955 Art silk Polymers 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010069729 Collateral circulation Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000531807 Psophiidae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101110640A CN100381125C (zh) | 2003-12-02 | 2003-12-02 | 一种治疗心脑血管病的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101110640A CN100381125C (zh) | 2003-12-02 | 2003-12-02 | 一种治疗心脑血管病的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1546052A CN1546052A (zh) | 2004-11-17 |
CN100381125C true CN100381125C (zh) | 2008-04-16 |
Family
ID=34335904
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2003101110640A Expired - Fee Related CN100381125C (zh) | 2003-12-02 | 2003-12-02 | 一种治疗心脑血管病的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100381125C (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1416817A (zh) * | 2002-11-29 | 2003-05-14 | 北京天衡药物研究院 | 灯盏花素分散片及其制备方法 |
CN1418646A (zh) * | 2001-11-12 | 2003-05-21 | 咸阳步长医药科技发展有限公司 | 一种用于治疗冠心病的中药及其制法 |
-
2003
- 2003-12-02 CN CNB2003101110640A patent/CN100381125C/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1418646A (zh) * | 2001-11-12 | 2003-05-21 | 咸阳步长医药科技发展有限公司 | 一种用于治疗冠心病的中药及其制法 |
CN1416817A (zh) * | 2002-11-29 | 2003-05-14 | 北京天衡药物研究院 | 灯盏花素分散片及其制备方法 |
Non-Patent Citations (2)
Title |
---|
参冠通片治疗冠心病心绞痛359例. 胡锦心等.空军总医院学报,第5卷第2期. 1989 * |
灯盏花素注射液治疗急性脑出血62例. 黄晓兰,陈娟.新乡医学院学报,第20卷第4期. 2003 * |
Also Published As
Publication number | Publication date |
---|---|
CN1546052A (zh) | 2004-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100447148C (zh) | 栀子提取物在制备治疗心脑血管病的药物中的应用 | |
CN101987112B (zh) | 一种治疗心脑血管病的药物组合物及其制备方法 | |
CN104055909A (zh) | 复方阿胶浆在制备经期保健的药物中的应用 | |
CN100381125C (zh) | 一种治疗心脑血管病的药物组合物 | |
CN100415241C (zh) | 一种治疗心脑血管病的药物组合物 | |
CN102940669B (zh) | 一种治疗心脑血管病的药物组合物 | |
CN102940668B (zh) | 一种治疗心脑血管病的药物组合物 | |
CN111558019B (zh) | 具有补气养血、调经止痛功效的中药组合物及其制备方法与应用 | |
CN102940676B (zh) | 一种治疗心脑血管病的药物组合物 | |
CN100408045C (zh) | 一种治疗心脑血管病的药物组合物 | |
CN104367630A (zh) | 一种含有西洋参的治疗心脑血管疾病的药物组合物 | |
CN102940675B (zh) | 一种治疗心脑血管病的药物组合物 | |
CN102940658A (zh) | 一种治疗心脑血管病的药物组合物 | |
CN102940694B (zh) | 一种治疗心脑血管病的药物组合物 | |
CN102940657A (zh) | 一种治疗心脑血管病的药物组合物 | |
CN104367656A (zh) | 一种含有山楂叶的治疗心脑血管疾病的药物组合物 | |
CN1562057A (zh) | 一种治疗心脑血管病的药物组合物 | |
CN101716253B (zh) | 一种活血化淤、益气养阴的中药制剂及其制备方法 | |
CN102940702B (zh) | 一种治疗心脑血管病的药物组合物 | |
CN104435213A (zh) | 一种含有柿子叶的治疗心脑血管病的中药组合物 | |
WO2004098623A1 (fr) | Injection intraveineuse de saponine de notoginseng et son procede de production | |
CN1528325A (zh) | 一种治疗心脑血管病的药物组合物 | |
CN104435664A (zh) | 一种含有赤小豆的治疗心脑血管疾病的药物组合物 | |
CN102406924B (zh) | 一种治疗脑血管与心血管疾病的药物组合物及其制备方法和用途 | |
CN104435074A (zh) | 一种含有红景天的治疗心脑血管疾病的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: CHONGQING HILAN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: LI WENJUN Effective date: 20100729 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 610041 6-11, 6/F, UNIT 2, BUILDING 12, NO.7, XIMIANQIAO STREET, WUHOU DISTRICT, CHENGDU CITY, SICHUAN PROVINCE TO: 401520 ZHOU NIANHUA, XIERAN AVENUE, HECHUAN INDUSTRY PARK, CHONGQING CITY |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100729 Address after: 401520 Chongqing city Hechuan Industrial Park Avenue hilan weeks time Patentee after: Chongqing Hilan Pharmaceutical Co., Ltd. Address before: 610041, 2, building 6, building 7, 12, wash Bridge Street, No. 6-11, Sichuan, Chengdu, Wuhou District Patentee before: Li Wenjun |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080416 Termination date: 20161202 |